166 related articles for article (PubMed ID: 31357131)
21. Hi-Fi SELEX: A High-Fidelity Digital-PCR Based Therapeutic Aptamer Discovery Platform.
Ouellet E; Foley JH; Conway EM; Haynes C
Biotechnol Bioeng; 2015 Aug; 112(8):1506-22. PubMed ID: 25727321
[TBL] [Abstract][Full Text] [Related]
22. Designing a new dimerized anti human TNF-α aptamer with blocking activity.
Mashayekhi K; Ganji A; Sankian M
Biotechnol Prog; 2020 Jul; 36(4):e2969. PubMed ID: 31989789
[TBL] [Abstract][Full Text] [Related]
23. A simple method for eliminating fixed-region interference of aptamer binding during SELEX.
Ouellet E; Lagally ET; Cheung KC; Haynes CA
Biotechnol Bioeng; 2014 Nov; 111(11):2265-79. PubMed ID: 24895227
[TBL] [Abstract][Full Text] [Related]
24. The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.
Nakanishi Y; Akiyama N; Tsukaguchi T; Fujii T; Sakata K; Sase H; Isobe T; Morikami K; Shindoh H; Mio T; Ebiike H; Taka N; Aoki Y; Ishii N
Mol Cancer Ther; 2014 Nov; 13(11):2547-58. PubMed ID: 25169980
[TBL] [Abstract][Full Text] [Related]
25. FGFR3 mRNA overexpression defines a subset of oligometastatic colorectal cancers with worse prognosis.
Fromme JE; Schmitz K; Wachter A; Grzelinski M; Zielinski D; Koppel C; Conradi LC; Homayounfar K; Hugo T; Hugo S; Lukat L; Rüschoff J; Ströbel P; Ghadimi M; Beißbarth T; Reuter-Jessen K; Bleckmann A; Schildhaus HU
Oncotarget; 2018 Aug; 9(63):32204-32218. PubMed ID: 30181810
[TBL] [Abstract][Full Text] [Related]
26. Identification of a novel variant form of fibroblast growth factor receptor 3 (FGFR3 IIIb) in human colonic epithelium.
Murgue B; Tsunekawa S; Rosenberg I; deBeaumont M; Podolsky DK
Cancer Res; 1994 Oct; 54(19):5206-11. PubMed ID: 7923141
[TBL] [Abstract][Full Text] [Related]
27. Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer.
Weickhardt AJ; Lau DK; Hodgson-Garms M; Lavis A; Jenkins LJ; Vukelic N; Ioannidis P; Luk IY; Mariadason JM
BMC Cancer; 2022 May; 22(1):478. PubMed ID: 35501832
[TBL] [Abstract][Full Text] [Related]
28. Mouse genetics identifies unique and overlapping functions of fibroblast growth factor receptors in keratinocytes.
Meyer M; Ben-Yehuda Greenwald M; Rauschendorfer T; Sänger C; Jukic M; Iizuka H; Kubo F; Chen L; Ornitz DM; Werner S
J Cell Mol Med; 2020 Jan; 24(2):1774-1785. PubMed ID: 31830366
[TBL] [Abstract][Full Text] [Related]
29. Artificial aptamer that inhibits interleukin-23/interleukin-23 receptor interaction discovered via SELEX.
Takamori Y; Ando T; Sato M; Vedi S; Fuji D; Yokoyama T; Tsukamoto K; Yamamoto M; Kawakami T
Biochem Biophys Res Commun; 2022 Jul; 614():17-21. PubMed ID: 35567939
[TBL] [Abstract][Full Text] [Related]
30. Fibroblast growth factor (FGF) 18 signals through FGF receptor 3 to promote chondrogenesis.
Davidson D; Blanc A; Filion D; Wang H; Plut P; Pfeffer G; Buschmann MD; Henderson JE
J Biol Chem; 2005 May; 280(21):20509-15. PubMed ID: 15781473
[TBL] [Abstract][Full Text] [Related]
31. An improved SELEX technique for selection of DNA aptamers binding to M-type 11 of Streptococcus pyogenes.
Hamula CL; Peng H; Wang Z; Tyrrell GJ; Li XF; Le XC
Methods; 2016 Mar; 97():51-7. PubMed ID: 26678795
[TBL] [Abstract][Full Text] [Related]
32. Development and Evaluation of Novel Aptamers Specific for Human PD1 Using Hybrid Systematic Evolution of Ligands by Exponential Enrichment Approach.
Khedri M; Abnous K; Rafatpanah H; Nabavinia MS; Taghdisi SM; Ramezani M
Immunol Invest; 2020 Jul; 49(5):535-554. PubMed ID: 32429721
[TBL] [Abstract][Full Text] [Related]
33. FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review).
Katoh M
Int J Mol Med; 2016 Jul; 38(1):3-15. PubMed ID: 27245147
[TBL] [Abstract][Full Text] [Related]
34. Upregulation of fibroblast growth factor receptor 2 and 3 in the late stages of fetal lung development in the nitrofen rat model.
Friedmacher F; Doi T; Gosemann JH; Fujiwara N; Kutasy B; Puri P
Pediatr Surg Int; 2012 Feb; 28(2):195-9. PubMed ID: 21994076
[TBL] [Abstract][Full Text] [Related]
35. SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy).
Aggarwal C; Redman MW; Lara PN; Borghaei H; Hoffman P; Bradley JD; Newman AJ; Feldman MJ; Minichiello K; Miao J; Mack PC; Papadimitrakopoulou VA; Herbst RS; Kelly K; Gandara DR
J Thorac Oncol; 2019 Oct; 14(10):1847-1852. PubMed ID: 31195180
[TBL] [Abstract][Full Text] [Related]
36. Fibroblast growth factor receptor (FGFR) gene amplifications are rare events in bladder cancer.
Fischbach A; Rogler A; Erber R; Stoehr R; Poulsom R; Heidenreich A; Schneevoigt BS; Hauke S; Hartmann A; Knuechel R; Veeck J; Gaisa NT
Histopathology; 2015 Apr; 66(5):639-49. PubMed ID: 24898159
[TBL] [Abstract][Full Text] [Related]
37. Potent inhibition of human immunodeficiency virus type 1 replication by template analog reverse transcriptase inhibitors derived by SELEX (systematic evolution of ligands by exponential enrichment).
Joshi P; Prasad VR
J Virol; 2002 Jul; 76(13):6545-57. PubMed ID: 12050367
[TBL] [Abstract][Full Text] [Related]
38. Selection and identification of an ssDNA aptamer to NB4 cell.
Zhang XH; Wang W; Chen X
J Clin Lab Anal; 2021 Apr; 35(4):e23718. PubMed ID: 33522630
[TBL] [Abstract][Full Text] [Related]
39. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4.
Hart KC; Robertson SC; Kanemitsu MY; Meyer AN; Tynan JA; Donoghue DJ
Oncogene; 2000 Jul; 19(29):3309-20. PubMed ID: 10918587
[TBL] [Abstract][Full Text] [Related]
40. Directionally specific paracrine communication mediated by epithelial FGF9 to stromal FGFR3 in two-compartment premalignant prostate tumors.
Jin C; Wang F; Wu X; Yu C; Luo Y; McKeehan WL
Cancer Res; 2004 Jul; 64(13):4555-62. PubMed ID: 15231666
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
